Brilaroxazine (RP-5063) is an atypical antipsychotic agent with potential for improving cognitive deficits associated with neuropsychiatric and neurological disorders; it shows efficacy in treating pulmonary arterial hypertension (PAH), mitigating functional and structural effects such as pulmonary hemodynamic impairment, right ventricular hypertrophy, reduced oxygen saturation (SO2), and pulmonary vascular remodeling.